Phytochemicals Used in Autoimmune Disorders

Year 2020, Volume: 40 Issue: 2, 83 - 92, 01.06.2020

Merve Bacanlı , Sevtap Aydın Dilsiz , Ahmet Başaran Nurşen Başaran

Abstract

The use of phytochemicals and herbs due to their therapeutic effects is as ancient as human, since their effective, safety and inexpensive properties are the main reasons of their usage. Phytochemicals have beneficial effects against different diseases including autoimmune disorders. The immune system provides the protection of human body from pathogens like bacteria, virus and fungi. Nevertheless, a breakdown in immune system often causes infections, diseases and autoimmune disorders. When immune system recognizes the heathy cells as foreign cells and attacks them, an immune disorder can develop. Multiple sclerosis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, thyroiditis, uveitis, systemic lupus erythromatosis, and myasthenia gravis are some of the known autoimmune disorders. This review aims to provide the readers a knowledge on the usage of phytochemicals against different autoimmune disorders.

Keywords

autoimmune disorder, phytochemical, plant

References

• 1. Venkatalakshmi P, Vadivel V, Brindha P: Role of phytochemicals as immunomodulatory agents: A review. International Journal of Green Pharmacy (IJGP) 2016, 10(1): 1-18. 2. Bravo L: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutrition reviews 1998. 56(11): 317-333. 3. Klaassen CD, Amdur MO: Casarett and Doull's toxicology: the basic science of poisons. McGraw-Hill; New York, USA, 2013. 4. Roberts SM, Adams L: Immunotoxicity: Toxic Effects on the Immune System. In: Principles of Toxicology: Environmental and Industrial Applications, Willey VCH; Weinheim, Germany. 2000: pp 189-206. 5. Chien S-C, Wu Y-C, Chen Z-W, Yang W-C: Naturally occurring anthraquinones: chemistry and therapeutic potential in autoimmune diabetes. Evidence-Based Complementary and Alternative Medicine 2015, 1: 1-13. 6. Cooper GS, Stroehla BC: The epidemiology of autoimmune diseases. Autoimmunity Reviews 2003, 2(3): 119-125. 7. Theofilopoulos AN, Kono DH, Baccala R: The multiple pathways to autoimmunity. Nature Immunology 2017, 18(7): 716-724. 8. IDF Diabetes Atlas. Brussels: International Diabetes Federation, 2013. 9. Lopomo A, Berrih-Aknin S: Autoimmune thyroiditis and myasthenia gravis. Frontiers in Endocrinology 2017, 8: 169. 10. Retamozo S, Brito-Zeron P, Quartuccio L, De Vita S, Ramos-Casals M: Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection. Expert Review of Clinical Pharmacology 2017, 10(10): 1085-1101. 11. Aggarwal BB: Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology 2003, 3(9): 745-756. 12. Aggarwal BB, Harikumar KB: Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The International Journal of Biochemistry & Cell Biology 2009, 41(1): 40-59. 13. Lorenz MH, Herrmann M, Kalden JR: The pathogenesis of autoimmune diseases. Scandinavian Journal of Clinical and Laboratory Investigation. 2001, 61(235): 16-26. 14. Sethi G, Sung B, Aggarwal BB: Nuclear factor-κB activation: from bench to bedside. Experimental Biology and Medicine 2008, 233(1): 21-31. 15. Veldman C, Nagel A, Hertl M: Type I regulatory T cells in autoimmunity and inflammatory diseases. International Archives of Allergy and Immunology. 2006, 140(2): 174-183. 16. Kapoor A: Malignancy in kidney transplant recipients. Drugs 2008, 68(1): 11-19. 17. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami R T, Dyke DB: Immunosuppression: practice and trends. American Journal of Transplantation 2004, 4: 38-53. 18. Ponticelli C, Tarantino A, Camprise M, Montagnino G, Aroldi A, Passerini P: From cyclosporine to the future. Transplantation Proceedings 2004, 6 (2 Suppl): 557S-560S. 19. Wong G, Chapman JR: Cancers after renal transplantation. Transplantation Reviews 2008, 22(2): 141-149. 20. Lai J-H: Immunomodulatory effects and mechanisms of plant alkaloid tetrandrine in autoimmune diseases. Acta Pharmacologica Sinica 200, 23(12): 1093-1101. 21. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloerzel P-M, Infante-Duarte C, Brocke S, Zipp F: Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. The Journal of Immunology 2004, 173(9): 5794-5800. 22. Zipp F, Aktas O: The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends in Neurosciences 2006, 29(9): 518-527. 23. Carsons S: A review and update of Sjögren's syndrome: manifestations, diagnosis, and treatment. The American Journal of Managed Care 2001, 7(14 Suppl): S433-443. 24. Ikebe K, Nokubi T, Sajima H, Kobayashi S, Hata K, Ono T, Etttinger RL: Perception of dry mouth in a sample of community‐dwelling older adults in Japan. Special Care in Dentistry 2001, 21(2): 52-59. 25. Miyasaka N: Epidemiology and pathogenesis of Sjögren's syndrome. Japanese Journal of Clinical Medicine 1995, 53(10): 2367-2370. 26. Schein OD, Hochberg MC, Munoz B, Tielsch JM, Roche K, Provost T, Anhalt GJ, West S: Dry eye and dry mouth in the elderly: a population-based assessment. Archives of Internal Medicine 1999, 159(12): 1359-1363. 27. Yoshida S: Sjögren's syndrome. Japanese Journal of Clinical Medicine 1999, 57(2), 360-363. 28. Zhang NZ, Shi CS, Ya QP, Pan GX, Wang LL, Wen ZX, Li XC, Dong Y: Prevalence of primary Sjögren’s syndrome in China. Journal of Rheumatology 1995(10): 787-788. 29. Hsu S, Dickinson, D: A new approach to managing oral manifestations of Sjogren's syndrome and skin manifestations of lupus. Journal of Biochemistry and Molecular Biology 2006, 39(3): 229-239. 30. Hsu S, Dickinson DP, Qin H: Inhibition of autoantigen expression by (-)-epigallocatechin-3-gallate (the major constituent of green tea) in normal human cells. Journal of Pharmacology and Experimental Therapeutics 2005, 315(2): 805-811. 31. Gillespie K, Kodani I, Dickinson DP, Ogbureke KU, Camba AM, Wu M, Looney S, Chu T-C, Qin H, Bisch F: Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease. Life Sciences 2008, 83(17-18): 581-588. 32. Hsu SD, Dickinson DP, Qin H, Borke J, Ogbureke KU, Winger JN, Camba AM, Bollag WB, Stöppler HJ, Sharawy MM: Green tea polyphenols reduce autoimmune symptoms in a murine model for human Sjogren's syndrome and protect human salivary acinar cells from TNF-α-induced cytotoxicity. Autoimmunity 2007, 40(2): 138-147. 33. Varilek GW, Yang F, Lee EY, DeVilliers WJ, Zhong J, Oz HS, Westberry KF, McClain CJ: Green tea polyphenol extract attenuates inflammation in interleukin-2–deficient mice, a model of autoimmunity. The Journal of Nutrition 2001, 131(7): 2034-2039. 34. Kim HR, Rajaiah R, Wu Q-L, Satpute SR, Tan MT, Simon JE, Berman BM, Moudgil KD: Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. The Journal of Nutrition 2008, 138(11): 2111-2116. 35. Hatcher H, Planalp R, Cho J, Torti F, Torti S: Curcumin: from ancient medicine to current clinical trials. Cellular and Molecular Life Sciences 2008, 65(11): 1631-1652. 36. Jeong W-S, Kim I-W, Hu R, Kong A-NT: Modulatory properties of various natural chemopreventive agents on the activation of NF-κB signaling pathway. Pharmaceutical Research 2004, 21(4): 661-670. 37. Thangapazham RL, Sharma A, Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. The AAPS Journal 2006, 8(3): E443. 38. Kim JH, Gupta SC, Park B, Yadav VR, Aggarwal BB: Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)‐κB and NF‐κB‐regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Molecular Nutrition & Food Research 2012, 56(3): 454-465. 39. Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C: Potential anticancer properties and mechanisms of action of curcumin. Anticancer Research 2015, 35(2): 645-651. 40. Deters M, Knochenwefel H, Lindhorst D, Koal T, Meyer HH, Hänsel W, Resch K, Kaever V: Different curcuminoids inhibit T-lymphocyte proliferation independently of their radical scavenging activities. Pharmaceutical Research 2008, 25(8): 1822. 41. Hushmendy S, Jayakumar L, Hahn AB, Bhoiwala D, Bhoiwala DL, Crawford DR: Select phytochemicals suppress human T-lymphocytes and mouse splenocytes suggesting their use in autoimmunity and transplantation. Nutrition Research 2009, 29(8): 568-578. 42. Ranjan D, Johnston TD, Wu G, Elliott L, Bondada S, Nagabhushan M: Curcumin blocks cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation. Journal of Surgical Research 1998, 77(2), 174-178. 43. Jackson J, Higo T, Hunter W, Burt H: The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflammation Research 2006, 55(4): 168-175. 44. Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G, Stafford G, Chen G, Lantz RC, Jolad SD: Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2006, 54(11), 3452-3464. 45. Park C, Moon D-O, Choi I-W, Choi BT, Nam T-J, Rhu C-H, Kwon TK, Lee WH, Kim G-Y, Choi YH: Curcumin induces apoptosis and inhibits prostaglandin E2 production in synovial fibroblasts of patients with rheumatoid arthritis. International Journal of Molecular Medicine 2007, 20(3): p. 365-372. 46. Zunino SJ, Storms DH, Stephensen CB: Diets rich in polyphenols and vitamin A inhibit the development of type I autoimmune diabetes in nonobese diabetic mice. The Journal of Nutrition, 2007, 137(5): 1216-1221. 47. Verbeek R, Plomp AC, van Tol EA, van Noort JM: The flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cells. Biochemical Pharmacology 2004, 68(4): 621-629. 48. Milenković M, Arsenović-Ranin N, Stojić-Vukanić Z, Bufan B, Vučićević D, Jančić I: Quercetin ameliorates experimental autoimmune myocarditis in rats. Journal of Pharmacy & Pharmaceutical Sciences 2010, 13(3): 311-319. 49. Ganju L, Karan D, Chanda S, Srivastava K, Sawhney R, Selvamurthy W: Immunomodulatory effects of agents of plant origin. Biomedicine & Pharmacotherapy 2003, 57(7): 296-300. 50. Bouic P, Lamprecht, JH: Plant sterols and sterolins: a review of their immune-modulating properties. Alternative Medicine Reviews 1999, 4(3): 170-177. 51. Dinkova‐Kostova, AT, Talalay P: Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Molecular Nutrition & Food Research 2008, 52(S1): S128-S138. 52. Juge N, Mithen R, Traka M: Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cellular and Molecular Life Sciences 2007, 64(9): 1105. 53. Wenzig E, Widowitz U, Kunert O, Chrubasik S, Bucar F, Knauder E, Bauer R: Phytochemical composition and in vitro pharmacological activity of two rose hip (Rosa canina L.) preparations. Phytomedicine 2008, 15(10): 826-835. 54. Willich S, Rossnagel K, Roll S, Wagner A, Mune O, Erlendson J, Kharazmi A, Sörensen H, Winther K: Rose hip herbal remedy in patients with rheumatoid arthritis–a randomised controlled trial. Phytomedicine 2010, 17(2): 87-93. 55. Burgos R, Hancke J, Bertoglio J, Aguirre V, Arriagada S, Calvo M, Cáceres D: Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clinical Rheumatology 2009, 28(8): 931-946. 56. Tan WD, Liao W, Zhou S, Wong WF: Is there a future for andrographolide to be an anti-inflammatory drug? Deciphering its major mechanisms of action. Biochemical Pharmacology 2017, 139: 71-81. 57. Li Z-z, Tan J-p, Wang L-l, Li Q-h: Andrographolide benefits rheumatoid arthritis via inhibiting MAPK pathways. Inflammation 2017, 40(5): 1599-1605.